Home  »  Finance   »  Recursion Pharmaceuticals Inc. (RXRX) – Don&...

Recursion Pharmaceuticals Inc. (RXRX) – Don’t Be So Quick to Call it Dead

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is -36.60% lower on its value in year-to-date trading and has touched a low of $4.92 and a high of $27.26 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RXRX stock was last observed hovering at around $10.94 in the last trading session, with the day’s loss setting it -0.08% off its average median price target of $13.00 for the next 12 months. It is also 71.42% off the consensus price target high of $38.00 offered by 6 analysts, but current levels are -35.75% lower than the price target low of $8.00 for the same period.

Currently trading at $10.86, the stock is -5.19% and 6.58% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.04 million and changing -0.73% at the moment leaves the stock 8.47% off its SMA200. RXRX registered -57.38% loss for a year compared to 6-month gain of 55.36%.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The stock witnessed a 12.54% loss in the last 1 month and extending the period to 3 months gives it a 26.87%, and is -19.38% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.65% over the week and 8.86% over the month.

Recursion Pharmaceuticals Inc. (RXRX) has around 400 employees, a market worth around $2.28B and $18.10M in sales. Distance from 52-week low is 120.73% and -60.16% from its 52-week high. The company has generated returns on investments over the last 12 months (-33.80%).

Recursion Pharmaceuticals Inc. (RXRX) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Recursion Pharmaceuticals Inc. (RXRX) is a “Overweight”. 6 analysts offering their recommendations for the stock have an average rating of 2.80, where 4 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Recursion Pharmaceuticals Inc. is expected to release its quarterly report on 11/09/2022.The EPS is expected to shrink by -177.30% this year

Recursion Pharmaceuticals Inc. (RXRX) Top Institutional Holders

The shares outstanding are 172.21M, and float is at 144.31M with Short Float at 10.11%.

Recursion Pharmaceuticals Inc. (RXRX) Insider Activity

A total of 91 insider transactions have happened at Recursion Pharmaceuticals Inc. (RXRX) in the last six months, with sales accounting for 41 and purchases happening 50 times. The most recent transaction is an insider sale by Virani Shafique, the company’s Chief Business Officer. SEC filings show that Virani Shafique sold 10,000 shares of the company’s common stock on Sep 15 at a price of $13.36 per share for a total of $0.13 million. Following the sale, the insider now owns 93773.0 shares.

Recursion Pharmaceuticals Inc. disclosed in a document filed with the SEC on Sep 01 that Gibson Christopher (Chief Executive Officer) sold a total of 2,500 shares of the company’s common stock. The trade occurred on Sep 01 and was made at $10.50 per share for $26255.0. Following the transaction, the insider now directly holds 0.0 shares of the RXRX stock.

Still, SEC filings show that on Sep 01, Gibson Christopher (Chief Executive Officer) disposed off 36,566 shares at an average price of $10.34 for $0.38 million. The insider now directly holds 549,262 shares of Recursion Pharmaceuticals Inc. (RXRX).

Recursion Pharmaceuticals Inc. (RXRX): Who are the competitors?

The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading -0.76% down over the past 12 months and Pfizer Inc. (PFE) that is 0.00% lower over the same period. Novan Inc. (NOVN) is -76.16% down on the 1-year trading charts.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.